This page shows the latest European biotech news and features for those working in and with pharma, biotech and healthcare.
This includes Lilly’s bamlanivimab and etesevimab combination, Roche and Regeneron’s REGEN-COV (casirivimab and imdevimab), Celltrion’s regdanivimab and GlaxoSmithKline/Vir Biotech’s sotrovimab. ... The European Medicines Agency (EMA) is
eureKARE has launched with a $60m Series A financing round to bolster the next-generation of European biotech companies working in the fields of the microbiome and synthetic biology. ... eureKARE has set up biotech start-up studio models – eureKABIOME
The vaccine also demonstrated early indications of functional T cells, confirming activation of cellular immune response according to the German biotech company. ... The European Commission (EC) has already secured 405 million doses of CVnCoV which will
The biotech has also managed to increase its share price since its launch, a feat not frequently achieved in the sector. ... a new surge in confidence in European biotech.
stage European biotechs, which have tended not have access to as much financial support as their counterparts in the US. ... to Medicxi, with European companies growing in stature and offering improved returns on investment for backers.
Boost for UK's golden triangle biotech region. Illumina has set up its first hub for genomics start-up funding outside the US, and has chosen Cambridge in the UK for
More from news
Approximately 22 fully matching, plus 36 partially matching documents found.
Healx is based in Cambridge, UK, a key European biotech hub, and was founded in 2014 by Dr Tim Guilliams, a biochemical engineer and founder of the Cambridge Rare Disease Network, ... Why will the company make it in the high-risk, highly competitive
Germany is European biotech’s sleeping giant. “Germany is Europe’s great untapped player in biotech,” said Richard. ... produced far fewer biotech companies than you would expect, it’s definitely the place to watch.”.
biotechs’. The growing role of specialist venture capital. One of the key ingredients in these and other recent European biotech success stories is long-term backing from investors. ... European biotech is benefiting from this new support to translate
Cambridge's new Biomedical Campus is home to specialist NHS trusts, AstraZeneca's new HQ and biotech firms. ... How can the UK life science ecosystem produce even more biotech start-ups, and propel them to long-term success?
It’s long been recognised that one of the biggest factors holding back UK and European biotech success has been a paucity of leaders, and that’s why efforts are being ... As well as overseeing the European communications group for Syneos Health, she
More from intelligence
Approximately 2 fully matching, plus 8 partially matching documents found.
Former general manager for Emmanuel Macron's party to spearhead Paris' bid to attract life sciences investment
With more than 25 years’ experience in initial public offerings, mergers and acquisitions, as well as licensing and financial transactions in the chemical, biotech and pharma industries, Llewellyn-Davies most recently ... He said: “Apeiron is
He is currently a board member of German biotech Epiontis, and has previously served as chief financial officer of PregLem and chairman of Aimago. ... Prior to this, Dr Zimmerman was a European biotech analyst at UBS Investment Bank.
Farquharson is additionally appointed to the EU Commission's Expert Group, advising on the European Biotech Directive's impact on patent law and R&D activities.
After an initial career in strategy consulting and investment banking, she held a number of senior management role at European biotech firms including CFO at Movetis, non-executive board member at
More from appointments
Approximately 1 fully matching, plus 5 partially matching documents found.
A specialist Advertising and Med Comms agency dedicated to bringing much-needed creativity to healthcare marketing. We believe that brilliant ideas...